Showing 20,141 - 20,160 results of 226,062 for search '(( 5 ((nn decrease) OR (mean decrease)) ) OR ( a ((point decrease) OR (a decrease)) ))', query time: 2.01s Refine Results
  1. 20141
  2. 20142

    Disparities in Hemoglobin A1c Testing During the Transition to Adulthood and Association With Diabetes Outcomes in Youth-Onset Type 1 and Type 2 Diabetes: The SEARCH for Diabetes i... by Katherine A Sauder (11126343)

    Published 2021
    “…For type 2 diabetes, not seeing an endocrinologist decreased odds of reporting ≥3 HbA1c tests/year over time (OR 0.19 [0.06-0.63]), but HbA1c testing frequency was not associated with HbA1c levels or microvascular complications.…”
  3. 20143
  4. 20144
  5. 20145

    Loss of Arid3b in Bone Marrow Results in Decreased B cells. by Jeffrey L. Kurkewich (3044211)

    Published 2016
    “…<p>For analysis of hematopoietic populations by flow cytometry, bone marrow was harvested from <i>Arid3b</i><sup><i>fl/fl</i></sup>: <i>Mx1-Cre</i> (denoted Arid3b<sup>-/-</sup>) mice 12 weeks after final pIpC injection. <b>A)</b> Representative FACS plot of B cell (B220+) and myeloid populations (CD11b+) in control or arid3b<sup>-/-</sup> mice. …”
  6. 20146
  7. 20147
  8. 20148
  9. 20149
  10. 20150
  11. 20151
  12. 20152
  13. 20153
  14. 20154

    BDNF exon IV-containing transcript is decreased following acute ZP treatment. by Stephanie C. Licata (499829)

    Published 2013
    “…<p>There is a selective and significant decrease in BDNF exon IV-containing transcript following ZP treatment compared to VEH in the HIP (n= 4-7). ** <i>p</i> < 0.01. …”
  15. 20155

    N protein of SVCV decreases K48-linked ubiquitination of p53. by Shun Li (330132)

    Published 2019
    “…<p><b>(A)</b> Effects of inhibitors on N protein-mediated destabilization of p53. …”
  16. 20156

    Effect of dilution and DMSO concentration on the interaction of NF-κB/DNA complex with the inhibitors. by Rodrigo Villagomez (685829)

    Published 2015
    “…<p><b>a)</b> Effect of 1) active compound <b>1</b>; 2) inactive compound <b>4</b>; B1) control complex NF-κB:DNA target and B2) free DNA target, at four different dilutions of the system: I) Initial conditions; II) Inhibitor at ¾, NF-κB at ¾ and DNA target to ½ of initial concentration; III) Diluting inhibitor to ½, NF-κB to ½ and DNA target to ¼ of initial concentration and IV) Diluting inhibitor at ½, NF-κB at ½ and DNA target at ¼ of initial concentration. …”
  17. 20157
  18. 20158
  19. 20159
  20. 20160